{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:07:17Z","timestamp":1791572837437,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kamprad Foundation","award":["20150052"],"award-info":[{"award-number":["20150052"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["E0718301"],"award-info":[{"award-number":["E0718301"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Monitoring metabolites of tamoxifen, such as endoxifen, has been suggested as a strategy to ascertain therapeutic effect of tamoxifen therapy, but clinical guidelines are missing. Herein, we aim to investigate the outcome of endoxifen concentrations of low-dose tamoxifen, using change in mammographic breast density as a proxy for therapy response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In the randomized KARISMA-Tam (Karolinska Mammography project for risk prediction of breast cancer -Intervention Study with Tamoxifen) trial, including 5 doses of tamoxifen, measurements of plasma endoxifen concentrations, determination of CYP2D6 metabolizer status, and mammographic breast density change over the trial period were carried out. Association between endoxifen concentrations and relative mammographic breast density change after 6\u2009months treatment was analyzed using linear regression in a spline model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 824 women (335 premenopausal, 489 postmenopausal) were included. In analyses of premenopausal women, a spline model described a mammographic breast density decrease, equivalent to the mean (\u221218.5%) seen in women exposed to 20\u2009mg tamoxifen, at endoxifen concentrations of 2-3\u2009ng\/mL. The mammographic breast density decrease reached a nadir at endoxifen levels of 3\u2009ng\/mL and did not decrease further at higher endoxifen concentrations. Most intermediate and normal tamoxifen metabolizers (about 90% of all participants) reached an endoxifen concentration of more than 2\u2009ng\/mL at tamoxifen doses of 5 and 10\u2009mg. No mammographic breast density decrease was seen in the postmenopausal group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We have identified a possible window of effect on mammographic breast density at endoxifen concentrations of 2-3\u2009ng\/mL in premenopausal women, which corresponds to the doses of 5 and 10\u2009mg tamoxifen. Because mammographic breast density change was used as a surrogate marker for therapy response, results should be confirmed using clinically established outcomes measures.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djae280","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T15:54:51Z","timestamp":1731081291000},"page":"629-636","source":"Crossref","is-referenced-by-count":7,"title":["Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6608-8867","authenticated-orcid":false,"given":"Mattias","family":"Hammarstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-1556","authenticated-orcid":false,"given":"Marike","family":"Gabrielson","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Bergqvist","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Department of Surgery and Oncology, Capio St G\u00f6rans Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lundholm","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2254-2420","authenticated-orcid":false,"given":"Alessio","family":"Crippa","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0397-6538","authenticated-orcid":false,"given":"Magnus","family":"B\u00e4cklund","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8317-7829","authenticated-orcid":false,"given":"Yvonne","family":"Wengstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Neurobiology, Care Science and Society, Division of Nursing and Theme Cancer, Karolinska Comprehensive Cancer Centre, Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7938-8893","authenticated-orcid":false,"given":"Signe","family":"Borgquist","sequence":"additional","affiliation":[{"name":"Department of Oncology, Aarhus University Hospital and Aarhus University , Aarhus,","place":["Denmark"]},{"name":"Department of Clinical Sciences Lund, Oncology, Lund University and Sk\u00e5ne University Hospital , Lund,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Eliasson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-4319","authenticated-orcid":false,"given":"Jos\u00e9","family":"Tapia","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-5695","authenticated-orcid":false,"given":"Kamila","family":"Czene","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-9126","authenticated-orcid":false,"given":"Per","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Department of Oncology, S\u00f6dersjukhuset , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"2025040623580853900_djae280-B1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the trials","volume":"365","author":"Early Breast Cancer Trialists\u2018 Collaborative Group","year":"2005","journal-title":"Lancet"},{"key":"2025040623580853900_djae280-B2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/B:BREA.0000025406.31193.e8","article-title":"Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen","volume":"85","author":"Johnson","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"2025040623580853900_djae280-B3","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1373\/clinchem.2008.121756","article-title":"Pharmacogenomics of tamoxifen therapy","volume":"55","author":"Brauch","year":"2009","journal-title":"Clin Chem"},{"key":"2025040623580853900_djae280-B4","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2014.59.3673","article-title":"Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer","volume":"33","author":"He","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025040623580853900_djae280-B5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","article-title":"Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review","volume":"134","author":"Murphy","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2025040623580853900_djae280-B6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2133\/dmpk.DMPK-11-RV-084","article-title":"Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters","volume":"27","author":"Kiyotani","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"2025040623580853900_djae280-B7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/clpt.2013.186","article-title":"CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations","volume":"95","author":"Province","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"2025040623580853900_djae280-B8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.19.01535","article-title":"CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in patients with breast cancer","volume":"38","author":"He","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025040623580853900_djae280-B9","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.annonc.2021.07.005","article-title":"CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial","volume":"32","author":"He","year":"2021","journal-title":"Ann Oncol"},{"key":"2025040623580853900_djae280-B10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/jpm11030201","article-title":"Generating a precision endoxifen prediction algorithm to advance personalized tamoxifen treatment in patients with breast cancer","volume":"11","author":"Helland","year":"2021","journal-title":"JPM"},{"key":"2025040623580853900_djae280-B11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","article-title":"Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes","volume":"89","author":"Madlensky","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2025040623580853900_djae280-B12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.18.00307","article-title":"Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study","volume":"37","author":"Sanchez-Spitman","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025040623580853900_djae280-B13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3390\/jpm12040511","article-title":"(Z)-endoxifen and early recurrence of breast cancer: an explorative analysis in a prospective Brazilian study","volume":"12","author":"Almeida","year":"2022","journal-title":"J Pers Med"},{"key":"2025040623580853900_djae280-B14","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1200\/JCO.19.00507","article-title":"Tamoxifen pharmacogenetics and metabolism: the same is not the same","volume":"37","author":"Brauch","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025040623580853900_djae280-B15","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1200\/JCO.19.00504","article-title":"Tamoxifen metabolism and breast cancer recurrence: a question unanswered by CYPTAM","volume":"37","author":"Goetz","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025040623580853900_djae280-B16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13058-017-0916-4","article-title":"Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients","volume":"19","author":"Helland","year":"2017","journal-title":"Breast Cancer Res"},{"key":"2025040623580853900_djae280-B17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00280-020-04089-x","article-title":"Exposure-response analysis of endoxifen serum concentrations in early-breast cancer","volume":"85","author":"Sanchez-Spitman","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025040623580853900_djae280-B18","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1200\/JCO.20.02598","article-title":"Low-dose tamoxifen for mammographic density reduction: a randomized controlled trial","volume":"39","author":"Eriksson","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025040623580853900_djae280-B19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jnci\/djh106","article-title":"Tamoxifen and breast density in women at increased risk of breast cancer","volume":"96","author":"Cuzick","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2025040623580853900_djae280-B20","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1200\/JCO.2012.44.5015","article-title":"Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025040623580853900_djae280-B21","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1093\/oncolo\/oyac104","article-title":"Time to mammographic density decrease after exposure to tamoxifen","volume":"27","author":"Backlund","year":"2022","journal-title":"Oncologist"},{"key":"2025040623580853900_djae280-B22","doi-asserted-by":"crossref","first-page":"e00646","DOI":"10.1002\/prp2.646","article-title":"Predicting steady-state endoxifen plasma concentrations in breast cancer patients by CYP2D6 genotyping or phenotyping. Which approach is more reliable?","volume":"8","author":"Gusella","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"2025040623580853900_djae280-B23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10549-018-4690-5","article-title":"A comprehensive tool for measuring mammographic density changes over time","volume":"169","author":"Eriksson","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2025040623580853900_djae280-B24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/bcp.14500","article-title":"Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles","volume":"87","author":"Thoren","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025040623580853900_djae280-B25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10549-016-3932-7","article-title":"A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen","volume":"159","author":"Johansson","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2025040623580853900_djae280-B26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-021-00236-6","article-title":"Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial","volume":"7","author":"DeCensi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2025040623580853900_djae280-B27","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025040623580853900_djae280-B28","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1158\/1078-0432.CCR-20-4213","article-title":"Effect modifiers of low-dose tamoxifen in a randomized trial in breast noninvasive disease","volume":"27","author":"DeCensi","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025040623580853900_djae280-B29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2009.1420","article-title":"Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen","volume":"302","author":"Schroth","year":"2009","journal-title":"JAMA"},{"key":"2025040623580853900_djae280-B30","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/1078-0432.CCR-12-2153","article-title":"CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8","volume":"19","author":"Goetz","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025040623580853900_djae280-B31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/1878-0261.12865","article-title":"Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen","volume":"15","author":"Helland","year":"2021","journal-title":"Mol Oncol"},{"key":"2025040623580853900_djae280-B32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41416-023-02293-z","article-title":"Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women","volume":"129","author":"Hammarstrom","year":"2023","journal-title":"Br J Cancer"},{"key":"2025040623580853900_djae280-B33","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/ijc.34430","article-title":"Effects of tamoxifen on normal breast tissue histological composition: results from a randomised six-arm placebo-controlled trial in healthy women","volume":"152","author":"Gabrielson","year":"2023","journal-title":"Int J Cancer"},{"key":"2025040623580853900_djae280-B34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ijc.34939","article-title":"Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change","volume":"155","author":"Gabrielson","year":"2024","journal-title":"Int J Cancer"},{"key":"2025040623580853900_djae280-B35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10549-018-4768-0","article-title":"Association of reproductive history with breast tissue characteristics and receptor status in the normal breast","volume":"170","author":"Gabrielson","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2025040623580853900_djae280-B36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-013-2511-4","article-title":"CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy","volume":"139","author":"Teft","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2025040623580853900_djae280-B37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10549-013-2677-9","article-title":"Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment","volume":"141","author":"Lien","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"2025040623580853900_djae280-B38","doi-asserted-by":"crossref","first-page":"109074","DOI":"10.1016\/j.envres.2019.109074","article-title":"Altered activity of xenobiotic detoxifying enzymes at menopause\u2014a cross-sectional study","volume":"182","author":"Tsiokou","year":"2020","journal-title":"Environ Res"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djae280\/60836754\/djae280.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/4\/629\/60836754\/djae280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/4\/629\/60836754\/djae280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T23:58:42Z","timestamp":1743983922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/4\/629\/7887567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,8]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djae280","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,11,8]]}}}